DTR3 announcement is Director/PDMR Shareholding
03 March 2016
LIVANOVA PLC
LivaNova PLC (the “Company” or “LivaNova”) announces that, on 26 February 2016, the following persons discharging managerial responsibilities (“PDMRs”) received ordinary shares of £1.00 each in the capital of the Company (“Ordinary Shares”) in connection with the vesting of Sorin LTI Awards, as set out in the table below.
Name |
Number of Ordinary Shares Received |
Number of Ordinary Shares held by the PDMR |
Interest in the Company’s issued share capital |
André-Michel Ballester |
4,375 |
80,959 |
0.17 |
Edward Andrle |
1,577 |
16,029 |
0.03 |
Brian Sheridan |
1,077 |
13,051 |
0.03 |
Pritpal Shinmar |
782 |
1,270 |
0.003 |
Piero Vecchi |
496 |
1,899 |
0.004 |
This announcement is made pursuant to Disclosure and Transparency Rule 3.1.4R.
About LivaNova
LivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The company employs approximately 4,500 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.
LivaNova is listed on NASDAQ and listed on the Official List of the UK’s Financial Conduct Authority and traded on London Stock Exchange (LSE) under the ticker symbol “LIVN”.
For more information, please visit www.livanova.com, or contact:
Investor Relations: Vivid Sehgal Chief Financial Officer e-mail: investor.relations@livanova.com |
Investor Relations and Media: |
- End -